Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionnucleoside-triphosphatase regulator activity

DOCK3 RGPD2 RAPGEF6 P2RY12 TBC1D2B RGPD1 ARFGEF1 RALGAPA2 TBC1D17 FARP2 RAPGEF3 RGS17

5.10e-0550711912GO:0060589
GeneOntologyMolecularFunctionGTPase regulator activity

DOCK3 RGPD2 RAPGEF6 P2RY12 TBC1D2B RGPD1 ARFGEF1 RALGAPA2 TBC1D17 FARP2 RAPGEF3 RGS17

5.10e-0550711912GO:0030695
GeneOntologyMolecularFunctionGTPase activator activity

DOCK3 RGPD2 TBC1D2B RGPD1 ARFGEF1 RALGAPA2 TBC1D17 RGS17

2.70e-042791198GO:0005096
GeneOntologyCellularComponentsynaptonemal complex

MEI4 MLH3 BRCA1 BRCA2

1.40e-04461204GO:0000795
GeneOntologyCellularComponentsynaptonemal structure

MEI4 MLH3 BRCA1 BRCA2

1.40e-04461204GO:0099086
GeneOntologyCellularComponentlateral element

MEI4 BRCA1 BRCA2

1.67e-04191203GO:0000800
GeneOntologyCellularComponentnuclear ubiquitin ligase complex

CUL7 BRCA1 BRCA2 CDC16

1.79e-04491204GO:0000152
GeneOntologyCellularComponentDNA repair complex

BRCA1 BRCA2 PRKDC

3.00e-04231203GO:1990391
GeneOntologyCellularComponentinterphotoreceptor matrix

IMPG1 EYS

4.83e-0461202GO:0033165
GeneOntologyCellularComponentcytoplasmic periphery of the nuclear pore complex

RGPD2 RGPD1

8.95e-0481202GO:1990723
GeneOntologyCellularComponentubiquitin ligase complex

CUL7 FBH1 BRCA1 MEGF8 BRCA2 DCUN1D2 CDC16 UBR3

9.78e-043521208GO:0000151
DomainARM-type_fold

DOCK3 PDS5B ARFGEF1 CUL7 RALGAPA2 PELP1 AP2B1 LTN1 PDS5A PRKDC

5.85e-0533911810IPR016024
DomainTPR-like_helical_dom

RGPD2 NRDE2 RGPD1 CDC16 NUB1 PRKDC CFAP70 EDRF1

1.17e-042331188IPR011990
DomainARM-like

PDS5B ARFGEF1 CUL7 PELP1 AP2B1 LTN1 PDS5A PRKDC

3.19e-042701188IPR011989
DomainTPR-contain_dom

RGPD2 RGPD1 CDC16 PRKDC CFAP70 EDRF1

3.82e-041501186IPR013026
DomainPeptidase_A22B_SPP

SPPL2B SPPL2C

3.91e-0451182IPR007369
DomainPeptidase_A22B

SPPL2B SPPL2C

3.91e-0451182PF04258
DomainTPR_REGION

RGPD2 RGPD1 CDC16 PRKDC CFAP70 EDRF1

6.33e-041651186PS50293
DomainTPR

RGPD2 RGPD1 CDC16 PRKDC CFAP70 EDRF1

6.33e-041651186PS50005
DomainPSN

SPPL2B SPPL2C

8.14e-0471182SM00730
DomainRab_bind

RGPD2 RGPD1

8.14e-0471182PF16704
DomainGCC2_Rab_bind

RGPD2 RGPD1

8.14e-0471182IPR032023
DomainPreselin/SPP

SPPL2B SPPL2C

8.14e-0471182IPR006639
DomainUbiquitin-rel_dom

MYO7B FARP2 SACS RAPGEF3 NUB1 APBB1IP

1.12e-031841186IPR029071
DomainTransglut_N

TGM5 TGM2

1.38e-0391182PF00868
DomainTRANSGLUTAMINASES

TGM5 TGM2

1.38e-0391182PS00547
DomainCalx_beta

FREM1 FREM2

1.38e-0391182IPR003644
Domain-

TGM5 TGM2

1.38e-03911823.90.260.10
DomainAlpha_adaptinC2

GGA3 AP2B1

1.38e-0391182PF02883
DomainGln_gamma-glutamylTfrase_euk

TGM5 TGM2

1.38e-0391182IPR023608
DomainTransglutaminase_AS

TGM5 TGM2

1.38e-0391182IPR013808
DomainTransglutaminase_N

TGM5 TGM2

1.38e-0391182IPR001102
DomainTransglut_C

TGM5 TGM2

1.38e-0391182PF00927
DomainClathrin_a/b/g-adaptin_app_Ig

GGA3 AP2B1

1.38e-0391182IPR008152
DomainAlpha_adaptinC2

GGA3 AP2B1

1.38e-0391182SM00809
DomainCalx-beta

FREM1 FREM2

1.38e-0391182PF03160
DomainMFS_dom

SLC46A1 SLCO5A1 SLC46A3 SLC15A1 CLN3

1.61e-031341185IPR020846
DomainTransglutaminase_C

TGM5 TGM2

1.72e-03101182IPR008958
Domain-

RGPD2 RGPD1

1.72e-031011821.10.220.60
Domain-

RGPD2 NRDE2 RGPD1 CDC16 CFAP70 EDRF1

2.03e-0320711861.25.40.10
DomainGrip

RGPD2 RGPD1

2.10e-03111182SM00755
DomainTransglutaminase-like

TGM5 TGM2

2.10e-03111182IPR002931
DomainGRIP

RGPD2 RGPD1

2.10e-03111182PF01465
DomainTGc

TGM5 TGM2

2.10e-03111182SM00460
DomainTransglut_core

TGM5 TGM2

2.10e-03111182PF01841
DomainRan_BP1

RGPD2 RGPD1

2.51e-03121182PF00638
DomainRANBD1

RGPD2 RGPD1

2.51e-03121182PS50196
DomainCoatomer/clathrin_app_Ig-like

GGA3 AP2B1

2.51e-03121182IPR013041
DomainGRIP_dom

RGPD2 RGPD1

2.51e-03121182IPR000237
DomainGRIP

RGPD2 RGPD1

2.51e-03121182PS50913
Domain-

PDS5B ARFGEF1 CUL7 AP2B1 PDS5A PRKDC

2.88e-0322211861.25.10.10
DomainRanBD

RGPD2 RGPD1

2.95e-03131182SM00160
DomainRan_bind_dom

RGPD2 RGPD1

2.95e-03131182IPR000156
Domain-

DOK5 RGPD2 MYO7B TBC1D2B RGPD1 FARP2 OSBPL5 APBB1IP

3.40e-0339111882.30.29.30
DomainA/G_cyclase_CS

ADCY8 GUCY2F

5.06e-03171182IPR018297
DomainPH_dom-like

DOK5 RGPD2 MYO7B TBC1D2B RGPD1 FARP2 OSBPL5 APBB1IP

5.67e-034261188IPR011993
Domain-

ADCY8 GUCY2F

5.67e-031811823.30.70.1230
DomainNucleotide_cyclase

ADCY8 GUCY2F

5.67e-03181182IPR029787
DomainIon_trans_dom

TRPM4 KCNV1 CATSPER4 TRPV2

5.93e-031141184IPR005821
DomainIon_trans

TRPM4 KCNV1 CATSPER4 TRPV2

5.93e-031141184PF00520
DomainGuanylate_cyc

ADCY8 GUCY2F

6.31e-03191182PF00211
DomainGUANYLATE_CYCLASE_2

ADCY8 GUCY2F

6.31e-03191182PS50125
DomainA/G_cyclase

ADCY8 GUCY2F

6.31e-03191182IPR001054
DomainGUANYLATE_CYCLASE_1

ADCY8 GUCY2F

6.31e-03191182PS00452
DomainPA

SPPL2B SPPL2C

6.31e-03191182PF02225
DomainPA_domain

SPPL2B SPPL2C

6.31e-03191182IPR003137
DomainCYCc

ADCY8 GUCY2F

6.31e-03191182SM00044
Pubmed

A dual-activity topoisomerase complex regulates mRNA translation and turnover.

DOCK3 TRPM4 RAPGEF6 RHBDF1 SZT2 MED14 SPPL2B RALGAPA2 TBC1D17 SBNO2 GGA3 PCNX2 MEGF8 CLN3 TMEM268 OSBPL5 HMGXB3 WDR90 PRKDC

1.10e-0811051221935748872
Pubmed

miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype.

SMARCA5 BRCA1 BRCA2

1.68e-074122327385001
Pubmed

Systematic identification of factors for provirus silencing in embryonic stem cells.

RGPD2 SMARCA5 RGPD1 SBNO2 BRCA1 PELP1 CDC16

1.22e-06153122726365490
Pubmed

The nucleoporin RanBP2 tethers the cAMP effector Epac1 and inhibits its catalytic activity.

RGPD2 RGPD1 RAPGEF3

2.33e-068122321670213
Pubmed

APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer.

PDS5B BRCA2 PDS5A

6.81e-0611122322293751
Pubmed

A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.

BRCA1 BRCA2

1.22e-052122217924331
Pubmed

Oral contraceptive use and BRCA penetrance: a case-only study.

BRCA1 BRCA2

1.22e-052122219549808
Pubmed

Prevalence of BRCA1 and BRCA2 Mutations Among Patients With Ovarian, Primary Peritoneal, and Fallopian Tube Cancer in India: A Multicenter Cross-Sectional Study.

BRCA1 BRCA2

1.22e-052122234101484
Pubmed

Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study.

BRCA1 BRCA2

1.22e-052122220512419
Pubmed

Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.

BRCA1 BRCA2

1.22e-052122222053997
Pubmed

Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring.

BRCA1 BRCA2

1.22e-052122218200524
Pubmed

Fertility in women with BRCA mutations: a case-control study.

BRCA1 BRCA2

1.22e-052122219200971
Pubmed

Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.

BRCA1 BRCA2

1.22e-052122228212807
Pubmed

Heterozygous BRCA1 and BRCA2 and Mismatch Repair Gene Pathogenic Variants in Children and Adolescents With Cancer.

BRCA1 BRCA2

1.22e-052122235980168
Pubmed

BRCA mutations and risk of prostate cancer in Ashkenazi Jews.

BRCA1 BRCA2

1.22e-052122215131025
Pubmed

BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants.

BRCA1 BRCA2

1.22e-052122222425665
Pubmed

Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: a 10-year experience and reappraisal of its clinical utility.

BRCA1 BRCA2

1.22e-052122222425664
Pubmed

Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis.

BRCA1 BRCA2

1.22e-052122222970155
Pubmed

Anti-müllerian hormone levels and antral follicle count in women with a BRCA1 or BRCA2 germline pathogenic variant: A retrospective cohort study.

BRCA1 BRCA2

1.22e-052122234304065
Pubmed

Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer.

BRCA1 BRCA2

1.22e-052122226852015
Pubmed

Power spectral analysis of mammographic parenchymal patterns for breast cancer risk assessment.

BRCA1 BRCA2

1.22e-052122218175183
Pubmed

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.

BRCA1 BRCA2

1.22e-052122223810788
Pubmed

Breast cancer surgery trend changes since the introduction of BRCA1/2 mutation screening: a retrospective cohort analysis of 158 mutation carriers treated at a single institution.

BRCA1 BRCA2

1.22e-052122220972632
Pubmed

Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.

BRCA1 BRCA2

1.22e-052122218165636
Pubmed

Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.

BRCA1 BRCA2

1.22e-052122233558422
Pubmed

Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.

BRCA1 BRCA2

1.22e-052122233534430
Pubmed

BRCA 1, 2 mutation and earlier menopause: could BRCA 1,2 be used as predictor of menopause?

BRCA1 BRCA2

1.22e-052122234137566
Pubmed

BRCA1/2 Mutation Detection in the Tumor Tissue from Selected Polish Patients with Breast Cancer Using Next Generation Sequencing.

BRCA1 BRCA2

1.22e-052122233918338
Pubmed

Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.

BRCA1 BRCA2

1.22e-052122226181175
Pubmed

Mutational analysis of BRCA1 and BRCA2 in Mediterranean Spanish women with early-onset breast cancer: identification of three novel pathogenic mutations.

BRCA1 BRCA2

1.22e-052122214517958
Pubmed

Better life expectancy in women with BRCA2 compared with BRCA1 mutations is attributable to lower frequency and later onset of ovarian cancer.

BRCA1 BRCA2

1.22e-052122218559571
Pubmed

BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.

BRCA1 BRCA2

1.22e-052122218559594
Pubmed

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

BRCA1 BRCA2

1.22e-052122211981002
Pubmed

Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies.

BRCA1 BRCA2

1.22e-052122228199346
Pubmed

Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations.

BRCA1 BRCA2

1.22e-052122218092194
Pubmed

Investigating the relationship between BRCA1 and BRCA2 genes methylation profile and sperm DNA fragmentation in infertile men.

BRCA1 BRCA2

1.22e-052122231095775
Pubmed

Screening for Genetic Testing in Breast Cancer - Are We Missing the Full Picture?

BRCA1 BRCA2

1.22e-052122226254840
Pubmed

Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases.

BRCA1 BRCA2

1.22e-052122219491894
Pubmed

Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers.

BRCA1 BRCA2

1.22e-052122229116468
Pubmed

BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.

BRCA1 BRCA2

1.22e-052122226026974
Pubmed

[Germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in China Han people].

BRCA1 BRCA2

1.22e-052122215059511
Pubmed

BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases.

BRCA1 BRCA2

1.22e-052122212112655
Pubmed

Can soy phytoestrogens decrease DNA methylation in BRCA1 and BRCA2 oncosuppressor genes in breast cancer?

BRCA1 BRCA2

1.22e-052122222339411
Pubmed

Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.

BRCA1 BRCA2

1.22e-052122234906479
Pubmed

Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing.

BRCA1 BRCA2

1.22e-052122212376518
Pubmed

Characterization and in silico analyses of the BRCA1/2 variants identified in individuals with personal and/or family history of BRCA-related cancers.

BRCA1 BRCA2

1.22e-052122232599251
Pubmed

BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.

BRCA1 BRCA2

1.22e-052122228549976
Pubmed

Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women.

BRCA1 BRCA2

1.22e-052122228439188
Pubmed

Characterization of lung cancers in patients with BRCA germline variants: A multicenter series.

BRCA1 BRCA2

1.22e-052122236156322
Pubmed

Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.

BRCA1 BRCA2

1.22e-052122225311111
Pubmed

Loss of heterozygosity at BRCA1/2 loci in hereditary and sporadic ovarian cancers.

BRCA1 BRCA2

1.22e-052122219875889
Pubmed

Prevalence and Penetrance of BRCA1 and BRCA2 Germline Mutations in Colombian Breast Cancer Patients.

BRCA1 BRCA2

1.22e-052122228680148
Pubmed

Anticipation in hereditary breast cancer.

BRCA1 BRCA2

1.22e-052122212220452
Pubmed

Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes.

BRCA1 BRCA2

1.22e-052122225085752
Pubmed

BRCA mutation carriers do not have compromised ovarian reserve.

BRCA1 BRCA2

1.22e-052122224378620
Pubmed

Evidence that BRCA1- or BRCA2-associated cancers are not inevitable.

BRCA1 BRCA2

1.22e-052122222972572
Pubmed

Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples.

BRCA1 BRCA2

1.22e-052122227793035
Pubmed

BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma.

BRCA1 BRCA2

1.22e-052122219064968
Pubmed

[Mutational analysis of BRCA1 and BRCA2 genes in early-onset breast cancer patients in Shanghai].

BRCA1 BRCA2

1.22e-052122216324400
Pubmed

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.

BRCA1 BRCA2

1.22e-052122214576434
Pubmed

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.

BRCA1 BRCA2

1.22e-052122228356425
Pubmed

[Molecular alterations in breast cancer: clinical implications and new analytical tools].

BRCA1 BRCA2

1.22e-052122215936476
Pubmed

Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations: a qualitative study of patient preferences.

BRCA1 BRCA2

1.22e-052122222736296
Pubmed

High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.

BRCA1 BRCA2

1.22e-052122227553291
Pubmed

The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers.

BRCA1 BRCA2

1.22e-052122215131400
Pubmed

An audit of screening for familial breast cancer before 50 years in the South Thames Region - have we got it right?

BRCA1 BRCA2

1.22e-052122215131403
Pubmed

BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles.

BRCA1 BRCA2

1.22e-052122226335130
Pubmed

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers.

BRCA1 BRCA2

1.22e-052122236203093
Pubmed

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

BRCA1 BRCA2

1.22e-052122212677558
Pubmed

Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations.

BRCA1 BRCA2

1.22e-052122217307836
Pubmed

Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer.

BRCA1 BRCA2

1.22e-052122212100744
Pubmed

High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.

BRCA1 BRCA2

1.22e-052122217997147
Pubmed

Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.

BRCA1 BRCA2

1.22e-052122216912212
Pubmed

Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue.

BRCA1 BRCA2

1.22e-052122219606050
Pubmed

Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.

BRCA1 BRCA2

1.22e-052122232066851
Pubmed

Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers.

BRCA1 BRCA2

1.22e-052122225919761
Pubmed

BRCA mutations and reproduction.

BRCA1 BRCA2

1.22e-052122229307397
Pubmed

Improved survival in women with BRCA-associated ovarian carcinoma.

BRCA1 BRCA2

1.22e-052122212712470
Pubmed

Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime Time.

BRCA1 BRCA2

1.22e-052122227283172
Pubmed

Low contribution of BRCA1/2 genomic rearrangement to high-risk breast cancer in the Korean population.

BRCA1 BRCA2

1.22e-052122219669600
Pubmed

Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype.

BRCA1 BRCA2

1.22e-052122220406939
Pubmed

Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy.

BRCA1 BRCA2

1.22e-052122221898151
Pubmed

Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients.

BRCA1 BRCA2

1.22e-052122226183948
Pubmed

Prevalent versus incident breast cancers: benefits of clinical and radiological monitoring in women with pathogenic BRCA1/2 variants.

BRCA1 BRCA2

1.22e-052122235217802
Pubmed

BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma.

BRCA1 BRCA2

1.22e-052122229309945
Pubmed

Molecular and in silico analysis of BRCA1 and BRCA2 variants.

BRCA1 BRCA2

1.22e-052122218694767
Pubmed

Body weight and risk of breast cancer in BRCA1/2 mutation carriers.

BRCA1 BRCA2

1.22e-052122220730487
Pubmed

Diagnostic criteria for testing for BRCA1 and BRCA2: the experience of the Department of Defense Familial Breast/Ovarian Cancer Research Project.

BRCA1 BRCA2

1.22e-052122211873550
Pubmed

BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations.

BRCA1 BRCA2

1.22e-052122234884434
Pubmed

Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.

BRCA1 BRCA2

1.22e-052122230756284
Pubmed

Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity.

BRCA1 BRCA2

1.22e-052122231492746
Pubmed

BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases.

BRCA1 BRCA2

1.22e-052122218645608
Pubmed

Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary.

BRCA1 BRCA2

1.22e-052122221394826
Pubmed

Screening of 1331 Danish breast and/or ovarian cancer families identified 40 novel BRCA1 and BRCA2 mutations.

BRCA1 BRCA2

1.22e-052122221318380
Pubmed

High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia.

BRCA1 BRCA2

1.22e-052122217080309
Pubmed

BRCA1/2 mutations are not a common cause of malignant melanoma in the Polish population.

BRCA1 BRCA2

1.22e-052122230286154
Pubmed

Psychosocial predictors of BRCA counseling and testing decisions among urban African-American women.

BRCA1 BRCA2

1.22e-052122212496047
Pubmed

Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

BRCA1 BRCA2

1.22e-052122223569316
Pubmed

Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers.

BRCA1 BRCA2

1.22e-052122231213659
Pubmed

Uptake of testing for BRCA1/2 mutations in South East Scotland.

BRCA1 BRCA2

1.22e-052122218285832
InteractionGPR17 interactions

PDS5B ARFGEF1 SPG11 INTS3 RAB18 SACS LTN1 UBR3 PDS5A PRKDC

7.59e-0628312010int:GPR17
Cytoband13q12.3

PDS5B SLC46A3 BRCA2

2.72e-0522122313q12.3
GeneFamilyTransglutaminases

TGM5 TGM2

5.68e-049732773
GeneFamilyTetratricopeptide repeat domain containing|Bardet-Biedl syndrome associated|BBSome

RGPD2 RGPD1 CDC16 CFAP70

1.21e-03115734769
ToppCellfacs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RELN MYO7B PKHD1L1 FREM1 FREM2 GUCY2F SDK1

7.69e-0718412272cbed6462fea2622871bb7e49b0df3d984239281
ToppCellfacs-Thymus-Thymus_Epithelium-18m-Lymphocytic|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RELN MYO7B PKHD1L1 FREM1 FREM2 GUCY2F SDK1

7.69e-071841227ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCellfacs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RELN MYO7B PKHD1L1 FREM1 FREM2 GUCY2F SDK1

7.69e-0718412272b19a8c5f823e00812908b23e66bb4e563278aff
ToppCellLPS_only-Endothelial-Endothelial-Activated_Alv_Cap|LPS_only / Treatment groups by lineage, cell group, cell type

PDE4B OAS2 PARP14 RALGAPA2 TGM2 SYNE2 NUB1

1.34e-062001227edb64556b3fefe3144f73b6efe23b9ffd34091d2
ToppCellSigmoid-T_cell-cycling_gd_T|T_cell / Region, Cell class and subclass

PRC1 ZNF587B BRCA1 BRCA2 LRRN2 RGS17 PEAK1

1.34e-0620012274e489ecf472857357d45e9f6c7a812aa48b72ebf
ToppCellCOVID-19-kidney-Lymphatic_EC|kidney / Disease (COVID-19 only), tissue and cell type

RELN PDE4B RALGAPA2 PKHD1L1 ACKR3 RGS17

6.77e-06167122697d0fea1f41c1c00e36d9b5c4c1f0dd85087056f
ToppCellCOVID-19-kidney-PEC|COVID-19 / Disease (COVID-19 only), tissue and cell type

XKR4 ABCB1 RAPGEF3 SYNE2 RGS17 SDK1

7.00e-061681226a086c306be430adf0632ba53e98cd8014d2de330
ToppCelldroplet-Heart-HEART-1m-Endothelial-leukocyte|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RELN SUSD4 ACR GOLM1 PKHD1L1 GNAL

8.28e-0617312269dc7746a84f0e268a7c061e1bbcd5e31903034dc
ToppCell5'-Adult-LymphNode-Endothelial-lymphatic_endothelial-LEC1_(ACKR4+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract

DOK5 RALGAPA2 PKHD1L1 TGM2 ACKR3 OSBPL5

1.14e-0518312262d0d3b486498a7903fa9a1f48b189291da49c430
ToppCellSomatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L2-4_PVALB_C8orf4|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types

HTR4 ADCY8 EYS ACKR3 GNAL SDK1

1.41e-05190122639ab890104b4264c68a968f920f4ccd84f0bc681
ToppCellCOVID-19-Heart-EC_(POSTN)|Heart / Disease (COVID-19 only), tissue and cell type

DOK5 RALGAPA2 PKHD1L1 PCED1B TGM2 NOSTRIN

1.50e-051921226c0c34785a7bdf461722029b322e9184e3d9b3c26
ToppCellControl-Endothelial-Endothelial|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

SUSD4 PDE4B AFF3 RALGAPA2 ABCB1 NOSTRIN

1.54e-051931226aff0649c73c634bc6ff0dc7759b4693a9236bf05
ToppCellControl-Endothelial|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

SUSD4 PDE4B AFF3 RALGAPA2 ABCB1 NOSTRIN

1.54e-051931226c5f9fe03e64c211d4bcd4959e5b32f14841e336a
ToppCellSmart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_pro-infl_I|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

P2RY12 OAS2 PARP14 FCGBP PADI2 APBB1IP

1.63e-051951226b6bf75669f267ecdc96818c7022db852e37a9fe1
ToppCellParenchyma_Control_(B.)-Endothelial-TX-Endothelial-1|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type

ACR PKHD1L1 ABCB1 RAPGEF3 SYNE2 NOSTRIN

1.73e-051971226f969685dee212f33a6f09e54c0cd1fd24ffef546
ToppCellLung_Parenchyma-Control-Endothelial-Endothelial-Endothelial-1|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)

ACR PKHD1L1 ABCB1 RAPGEF3 SYNE2 NOSTRIN

1.73e-0519712261a137af40697137bb9d2b5caf2b1ffda55f04461
ToppCellLung_Parenchyma-Control-Endothelial-Endothelial-Endothelial-1-|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

ACR PKHD1L1 ABCB1 RAPGEF3 SYNE2 NOSTRIN

1.73e-05197122696d63a8d00583e2aa0a38412e2ae27e23f399493
ToppCellSmart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_pro-infl_I-G|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

P2RY12 OAS2 PARP14 FCGBP PADI2 APBB1IP

1.78e-051981226cc808d872d2404a79ec119bb0be62688a30c93a7
ToppCellLPS_IL1RA_TNF-Endothelial-Endothelial-Activated_Alv_Cap|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type

PDE4B OAS2 PARP14 TGM2 SYNE2 NUB1

1.89e-05200122689821a264e872ed53e08e9d3609d5cc5c314503e
ToppCellVE|World / Condition, Cell_class and T cell subcluster

FAM89B OAS2 PARP14 SYNE2 NUB1 APBB1IP

1.89e-0520012268ae7cb81de3ffac5acdf3466d4b516d80cac95d3
ToppCellLPS-IL1RA-Endothelial-Mes-Like-Gen_Cap|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

PCED1B EYS SLC15A1 SACS LRRN2

4.97e-05145122590ca38c02325c5c637c32efdef634b54cc3cd105
ToppCellfacs-Diaphragm-Limb_Muscle-18m-Myeloid-nan|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

P2RY12 HACD4 LRRC4 IL1A PADI2

5.13e-05146122569cbe8d4772f8e46a5e1a1cdca0e370308a97b4f
ToppCellCOVID-19-kidney-Lymphatic_EC|COVID-19 / Disease (COVID-19 only), tissue and cell type

RELN RALGAPA2 PKHD1L1 ACKR3 RGS17

5.48e-051481225f777aa1674e898e2594b2b7c029d3d05dda04df9
ToppCellBAL-Mild-Myeloid-TRAM-TRAM2-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

TGM2 FBH1 FITM1 IL1A WDR17

6.02e-05151122528e3f77d2edb30fcf1414762a55ceffaf879d526
ToppCellBAL-Mild-Myeloid-TRAM-TRAM2|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

TGM2 FBH1 FITM1 IL1A WDR17

6.02e-051511225688cc5e4d46ba16f9b431352d7a6d39b21941e9c
ToppCellBAL-Mild-Myeloid-TRAM-TRAM2-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

TGM2 FBH1 FITM1 IL1A WDR17

6.02e-05151122545392bb1c6358beff33da0ca84f7696fb5824f30
ToppCellBAL-Mild-Myeloid-TRAM-TRAM2|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)

TGM2 FBH1 FITM1 IL1A WDR17

6.02e-0515112253d861285c71abe220b19a069eb9876199c6c8f39
ToppCellChildren_(3_yrs)-Epithelial-lung_goblet_cell-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor

SUSD4 GOLM1 FCGBP RGS17 GNAL

6.21e-0515212251b2a39ae159e79f1fb18d6d164bd7acab5299fca
ToppCellMild_COVID-19-Myeloid-TRAM2|Mild_COVID-19 / Disease group,lineage and cell class （2021.01.30）

TGM2 FBH1 FITM1 IL1A WDR17

6.61e-051541225ab648f6b29eb9e499e46cbdbaf3c5cf6b94d1f64
ToppCellfacs-Marrow-B-cells-24m-Lymphocytic-precursor_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

MYO7B PKHD1L1 ADCY8 FREM1 WDR17

7.92e-051601225c381ec6be8cf887861cc18f831a20db42f953fe1
ToppCellfacs-Marrow-B-cells-24m-Lymphocytic-pre_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

MYO7B PKHD1L1 ADCY8 FREM1 WDR17

7.92e-05160122525c8f3d2a6d14ff0ca0b965fce89d3ff22f40585
ToppCellfacs-Kidney-nan-3m-Lymphocytic-T_cell|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PCED1B BRCA1 PADI2 APBB1IP IQCK

8.64e-051631225385b24e18df5ef92108483de312d6c85a1e6d145
ToppCellfacs-Kidney-nan-3m-Lymphocytic-T_cell|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PCED1B BRCA1 PADI2 APBB1IP IQCK

8.64e-0516312258004cc0b3428be08b89957b563cd8799f822d931
ToppCell368C-Myeloid-Dendritic-cDC_activated|Dendritic / Donor, Lineage, Cell class and subclass (all cells)

DOCK3 SLCO5A1 ACKR3 NUB1 NOSTRIN

9.16e-0516512259d2bdc42c13c8c2a68889bec8612a1ce56f659fa
ToppCellPND07-Immune-Immune_Myeloid-Monocytic-Macrophage-IM-IM_G2M|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

P2RY12 PRC1 ABCB1 BRCA1 TLR4

9.42e-051661225bb8135119dc37fdbba476599a56d368f422688dc
ToppCellCOVID-19-APC-like-Monocyte-derived_macrophages|COVID-19 / group, cell type (main and fine annotations)

OAS2 INTS3 MEI4 ADPRM PADI2

9.69e-051671225854a5dbd43f2b25825a71d37fd7779507783a99a
ToppCellChildren_(3_yrs)-Endothelial-endothelial_cell_of_vein-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor

HTR4 RALGAPA2 ABCB1 RAPGEF3 NOSTRIN

9.69e-051671225d7fe24cdc4b55a9555ce9e20699f5036b88148e9
ToppCellCOVID-19-Heart-CM_+_Macrophage|Heart / Disease (COVID-19 only), tissue and cell type

DOCK3 PDE4B SLCO5A1 FCGBP APBB1IP

1.05e-0417012254232fe937909f93d3736988c707b8f95ce993398
ToppCelldroplet-Kidney-KIDNEY-1m-Myeloid-nan|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PDS5B P2RY12 TBC1D2B TLR4 PADI2

1.08e-041711225d9ad6a3bce3556abd24af1630bf4a99594437c3a
ToppCellfacs-Trachea-3m-Mesenchymal-fibroblast-fibroblast_of_trachea-tracheal_fibroblast_l15|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

DOK5 SZT2 LRRN2 RGS17 APBB1IP

1.11e-041721225de4961f4037c439d3e0ec706a257b0ec17f4d5be
ToppCellEndothelial-B-IPF_04|World / lung cells shred on cell class, cell subclass, sample id

DOK5 RELN XKR4 PKHD1L1 ACKR3

1.11e-041721225d4e98ff9c7cbc95457e1d71fa60f151a2f178dae
ToppCellE16.5-Immune-Immune_Myeloid-Monocytic-Macrophage-IM|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

P2RY12 OAS2 HACD4 PARP14 APBB1IP

1.11e-041721225714172f31abd0d25261df6115ec6a9df491fa14b
ToppCellSmart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_prolif|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

OAS2 HACD4 FCGBP PADI2 APBB1IP

1.14e-0417312258407c9156ab35900858de5273586129d7e283c5b
ToppCelldroplet-Kidney-KIDNEY-30m-Mesenchymal-podocyte|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

TRPM4 PCED1B FCGBP BRCA2 PRKDC

1.21e-04175122531f0fb2e47e357dbf9c15436b7df85b3c370ded7
ToppCellClub_cells-IPF_02|World / lung cells shred on cell class, cell subclass, sample id

SUSD4 IMPG1 GOLM1 LRRC4 SYNE2

1.24e-04176122588c4ed0ab4a4ede8cad21385d799b723b5786cd9
ToppCellE16.5-Mesenchymal-Mesenchymal_structural-Fibroblastic-Mesothelial-Mesothelial_mature|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

IMPG1 GOLM1 PKHD1L1 TGM2 FREM2

1.31e-041781225a107dd98a07086ed0429116095ecda60c9dbef1e
ToppCell15-Trachea-Epithelial-Goblet-like_secretory|Trachea / Age, Tissue, Lineage and Cell class

GOLM1 TGM2 FCGBP RAPGEF3 RGS17

1.31e-041781225f0557920b9b3e7c4f39938d1b524aa58711af4d2
ToppCellCOVID-19-kidney-Epi_(Mes)|COVID-19 / Disease (COVID-19 only), tissue and cell type

RELN XKR4 RAPGEF3 SYNE2 SDK1

1.31e-041781225544379f5a6145429762258d426b876bb36c112f5
ToppCell5'-Adult-LymphNode-Endothelial-lymphatic_endothelial-LEC6_(ADAMTS4+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract

DOK5 RALGAPA2 PKHD1L1 TGM2 ACKR3

1.34e-0417912259fd9b136ecbcbd4e4f0d5875ede98d8d48608afb
ToppCellSmart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_prolif-G|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

OAS2 HACD4 FCGBP PADI2 APBB1IP

1.34e-0417912252832a9ea1c84b809f4bb5fb39d7ad50af4b33fa9
ToppCellP03-Mesenchymal-mesenchymal_fibroblast-mesothelial_cell_of_visceral_pleura|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

HACD4 PKHD1L1 PCNX2 TGM2 FREM2

1.38e-0418012252ccc77d769d3ffd77ab3af45e4f192785b6db79c
ToppCelldroplet-Heart-HEART_(LV+RV_ONLY)-30m-Endothelial-endocardial_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RELN SUSD4 PKHD1L1 TGM2 ACKR3

1.41e-041811225cef034030e6b029a49ae56be37ea1fac1a5c350e
ToppCellfacs-Brain_Non-Myeloid-Cortex-3m-Neuronal-medium_spiny_neuron|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

HTR4 PCNX2 KCNV1 MEI4 GNAL

1.45e-041821225d41ff834b8fc1d0e23cac7ae261de5f72874e462
ToppCell5'-Adult-Appendix-Endothelial-lymphatic_endothelial-LEC6_(ADAMTS4+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract

RELN RALGAPA2 PKHD1L1 TGM2 ACKR3

1.45e-041821225fd786c88826ad3d5cc5c3d80f8e392d6be1b5267
ToppCellfacs-Brain_Non-Myeloid-Cortex-3m-Neuronal-SPN_Neuron_STR|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

HTR4 PCNX2 KCNV1 MEI4 GNAL

1.45e-0418212256cde859edfe7607bd7ada89d20258413d06f4207
ToppCellChildren_(3_yrs)-Epithelial-lung_goblet_cell|Children_(3_yrs) / Lineage, Cell type, age group and donor

SUSD4 GOLM1 FCGBP RGS17 SDK1

1.45e-0418212253f1a666fe27dd7529c114539ed5f6b8ca585c875
ToppCellPrimary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L2-4_PVALB_C8orf4|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types

HTR4 ADCY8 EYS ACKR3 SDK1

1.49e-04183122504d3cc76038b8192c915f1c08c3e26f2ad3b3779
ToppCellB_cells-ISG-high_B_cells|World / Immune cells in Kidney/Urine in Lupus Nephritis

OAS2 PARP14 BRCA2 TMEM268 NUB1

1.49e-041831225dc2b00e920efa1dcc2a6265cd1024e3249c9974f
ToppCellFetal_29-31_weeks-Endothelial-endothelial_cell_of_vein-D150|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

TGM2 RAPGEF3 ACKR3 LRRN2 NOSTRIN

1.49e-041831225c1297d8eddfc7132e84ceef14f01b6281f9d0f6a
ToppCellControl-Endothelial_cells-Pulmonary_venous_endothelial_cells|Control / group, cell type (main and fine annotations)

RALGAPA2 PKHD1L1 ABCB1 TGM2 NOSTRIN

1.49e-04183122546be9f96755c7b65aeac061d95d15abeb6466034
ToppCell5'-GW_trimst-2-SmallIntestine-Endothelial-lymphatic_endothelial-LEC1_(ACKR4+)|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

RELN EXO5 PDE4B RALGAPA2 PKHD1L1

1.53e-04184122530ca56d64c961127e26122613e35aa2b46fde2df
ToppCell5'-Adult-Appendix-Endothelial-lymphatic_endothelial|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract

RELN RALGAPA2 PKHD1L1 TGM2 ACKR3

1.53e-041841225453295362888c9a59d0e73c7a5b15914c50ff591
ToppCellE17.5-Mesenchymal-mesenchymal_fibroblast-mesothelial_cell_of_visceral_pleura|E17.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

HACD4 PKHD1L1 PCNX2 TGM2 FREM2

1.53e-041841225607b55022de21ddb6a2d75e085df76df7abf6624
ToppCell343B-Fibroblasts-Fibroblast-E-|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)

GGA3 SLC46A3 GNAL ZNF418 APBB1IP

1.56e-0418512251b8e3ddb91797f84e4b15d2457b0c008e5be50db
ToppCell343B-Fibroblasts-Fibroblast-E|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)

GGA3 SLC46A3 GNAL ZNF418 APBB1IP

1.56e-04185122502cbf492bc40abebaa93a3a208888afae72fbe06
ToppCellCOVID-19-Endothelial_cells-Systemic_venous_endothelial_cells|COVID-19 / group, cell type (main and fine annotations)

RALGAPA2 ABCB1 RAPGEF3 SYNE2 NOSTRIN

1.56e-041851225f5e14181f45c37d13ee9e017a4c8bc248c353676
ToppCellSomatosensory_Cortex_(S1)-Non-neuronal-Endothelial_Myeloid-Endo-Endothelial-Endo_L2-5_CLDN5|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types

OAS2 ABCB1 TGM2 SYNE2 NOSTRIN

1.60e-041861225422d24e3e1a9397bb7d5c7ef75de2fd7ae8e136d
ToppCellSomatosensory_Cortex_(S1)-Non-neuronal-Endothelial_Myeloid-Endo|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types

OAS2 ABCB1 TGM2 SYNE2 NOSTRIN

1.60e-04186122565da0666a10a59f8cc379589860a2e98fe487754
ToppCellSomatosensory_Cortex_(S1)-Non-neuronal-Endothelial_Myeloid-Endo-Endothelial|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types

OAS2 ABCB1 TGM2 SYNE2 NOSTRIN

1.60e-041861225dc84fef1ca2f5d5d818b76a3321559e87d1c4a4d
ToppCellLPS-IL1RA+antiTNF-Endothelial-Endothelial-Activated_Alv_Cap|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

SUSD4 AFF3 OAS2 PARP14 ABCB1

1.64e-041871225f3397dbc23b6c2f24e2c1ba887d8f9aef3ee01a1
ToppCellLPS-IL1RA+antiTNF-Endothelial-Endothelial-Activated_Gen_Cap|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

SUSD4 OAS2 PARP14 ABCB1 NOSTRIN

1.64e-041871225dffa8447c2f3fdacf39a7258c6b4e81a25245041
ToppCellwk_15-18-Hematologic-Myeloid-Basophil|wk_15-18 / Celltypes from embryonic and fetal-stage human lung

OAS2 RALGAPA2 SLCO5A1 LTN1 TRPV2

1.69e-0418812253638d85452de15a060146628fbbad9d2a36feb13
ToppCellCOVID-19-lung-Vein_EC|lung / Disease (COVID-19 only), tissue and cell type

RALGAPA2 PKHD1L1 ABCB1 RAPGEF3 NOSTRIN

1.69e-041881225d582b76fc2faac526c9bf97503041129e1a6a211
ToppCellLPS-antiTNF-Endothelial-Endothelial-Alv_Gen_Intermediate|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

SUSD4 AFF3 OAS2 ABCB1 NOSTRIN

1.69e-041881225789d1be574e693d7bdd488f3c72c6df788e47b47
ToppCellIPF-Myeloid-cDC1|IPF / Disease state, Lineage and Cell class

AFF3 FARP2 SLCO5A1 PADI2 SDK1

1.69e-0418812252331a2bae1383820d598e93aa86c75b101069bac
ToppCellSmart-seq2-spleen_(Smart-seq2)|Smart-seq2 / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type

PDE4B MYO7B AFF3 FARP2 CDC37

1.73e-041891225b0244a9d1b5c8ad4708750b691184f3491b13900
ToppCellCOVID-19-Heart-EC_(POSTN)|COVID-19 / Disease (COVID-19 only), tissue and cell type

DOK5 RALGAPA2 PKHD1L1 TGM2 NOSTRIN

1.73e-0418912257346c1112e2e155dbd71b6dbc80e680fd262a691
ToppCellRA-10._Endothelium_II|World / Chamber and Cluster_Paper

RALGAPA2 PKHD1L1 PCED1B TGM2 NOSTRIN

1.73e-04189122575c248b9de5e2fb7a0baa8cdbab516e575cc4394
ToppCell3'-Distal_airway-Endothelial-Blood_vessel_EC-vein_endothelial_cell-EC_venous_systemic|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

DOK5 ABCB1 CDC37 ACKR3 NOSTRIN

1.73e-041891225e002dbb2138a6264be23f3b8148275a0cef351ef
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_cortex|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

RELN RALGAPA2 PKHD1L1 ACKR3 RGS17

1.77e-041901225876bd2eb9ed2624cb23bdcf6b989e4fa34d099e3
ToppCellILEUM-non-inflamed-(7)_Endothelial_cell-(7)_Lymphatics|(7)_Endothelial_cell / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)

RELN SUSD4 PDE4B PKHD1L1 ACKR3

1.77e-0419012259ce301841ce9486701fa28eb2a9929e35d476878
ToppCellSomatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types

HTR4 ADCY8 EYS GNAL SDK1

1.77e-0419012253f22c118d552345f731d4d49f0bcb5765d93de3b
ToppCellLPS-IL1RA+antiTNF-Endothelial-Endothelial-Alv_Gen_Intermediate|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

SUSD4 AFF3 OAS2 ABCB1 NOSTRIN

1.77e-041901225a3c6eec6df052105ab78b7e3c78f94218d5912eb
ToppCellCOVID-19-Heart-EC_3|Heart / Disease (COVID-19 only), tissue and cell type

RALGAPA2 ABCB1 PCED1B TGM2 NOSTRIN

1.77e-04190122578e7c502b0450c0b37652b1896a2a752fd8a2111
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_cortex-lymphatic_endothelial_cell_of_renal_cortex|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

RELN RALGAPA2 PKHD1L1 ACKR3 RGS17

1.77e-041901225be9f36127028f52ca5fc1b32ba15a6c26aad69ac
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Endothelial-lymphatic_endothelial_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

RELN RALGAPA2 PKHD1L1 ACKR3 RGS17

1.77e-04190122509a8855901c3c9332dbaab3e40166485b696d0f1
ToppCellprimary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L2-4_PVALB_C8orf4|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types

HTR4 ADCY8 EYS GNAL SDK1

1.77e-0419012250acf1d5da68db449d8c9e70519a236ce825f9d11
ToppCell5'-Adult-LymphNode-Endothelial-lymphatic_endothelial|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract

DOK5 RALGAPA2 PKHD1L1 TGM2 ACKR3

1.77e-0419012256b704deeb44e1ffa10e604d0e5612b022f6cd9a6
ToppCell(06)_Krt4/13+-(2)_48hpi|(06)_Krt4/13+ / shred by cell type and Timepoint

TGM5 TGM2 ADPRM

1.79e-044012231e42cd186ee06ac9345e16ede649a72c15bdf2f8
ToppCellFetal_29-31_weeks-Mesenchymal-matrix_fibroblast_1_cell-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

DOK5 TBC1D2B SBNO2 SLCO5A1 SDK1

1.81e-04191122508720998aa55131d7377c4c67c4c935865bd7d79
ToppCellLPS_only-Endothelial-Endothelial-Activated_Alv_Cap|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

SUSD4 AFF3 PARP14 ABCB1 TGM2

1.81e-041911225a7b18bcf27c38ad2353c239ecb309c80f3ef3359
ToppCellmetastatic_Lymph_Node-Myeloid_cells-CD207+CD1a+_LCs|Myeloid_cells / Location, Cell class and cell subclass

TRPM4 AFF3 FAM89B XKR4 FCGBP

1.86e-041921225f18da8db573e584c8b90df0814afcf020360108e
ToppCellRA-09._Endothelium_I|RA / Chamber and Cluster_Paper

RALGAPA2 PKHD1L1 RAPGEF3 SYNE2 NOSTRIN

1.86e-0419212258a1b1c3e83a68ad74f8f4eb00455c9e41aa57cfc
ToppCellfacs-Brain_Myeloid-Hippocampus-3m-Myeloid|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

SMARCA5 P2RY12 GOLM1 UBE2H APBB1IP

1.90e-04193122506b65110db974f4ef90d3511ff34428976a52c9c
ToppCellRV-10._Endothelium_II|RV / Chamber and Cluster_Paper

PARP14 RALGAPA2 PKHD1L1 PCED1B NOSTRIN

1.90e-04193122501c2df9206f1527c578e808978e58196c35e72f5
ToppCellfacs-Brain_Myeloid-Hippocampus-3m|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

SMARCA5 P2RY12 GOLM1 UBE2H APBB1IP

1.90e-041931225a4f91bca5eaa985982d33a528f7566ffde154d47
ToppCellrenal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Thick_Ascending_Limb_Cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

XKR4 UBE2H SLC15A1 SYNE2 SDK1

1.90e-041931225f42a0f02ed00fe1bb833ff0a0640d9131bca89bd
ToppCellRV-10._Endothelium_II|World / Chamber and Cluster_Paper

PARP14 RALGAPA2 PKHD1L1 SYNE2 NOSTRIN

1.90e-0419312252531266bc57339d4e2b22a88817008e32b8c1598
ToppCellrenal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

XKR4 UBE2H SLC15A1 SYNE2 SDK1

1.90e-04193122542df7ed37d11fb542b4d1d714b6f87ae8e1396a6
ToppCellfacs-Brain_Myeloid-Hippocampus-3m-Myeloid-nan|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

SMARCA5 P2RY12 GOLM1 UBE2H APBB1IP

1.90e-041931225b39d7feaac4ff8f7409cd3d15e8f3c6391367275
DrugThiethylperazine malate [52239-63-1]; Down 200; 6uM; PC3; HT_HG-U133A

PDS5B TRPM4 SZT2 TBC1D2B GGA3 FARP2 PCNX2 SLC46A3 EDRF1

1.21e-0619912195756_DN
DiseaseMental Depression

RELN PDE4B HTR4 OAS2 ADCY8 ABCB1 BRCA1 IL1A

8.21e-062541178C0011570
Diseaseductal carcinoma in situ (biomarker_via_orthology)

BRCA1 BRCA2

1.56e-0521172DOID:0060074 (biomarker_via_orthology)
DiseaseHereditary site-specific ovarian cancer syndrome

BRCA1 BRCA2

1.56e-0521172C4749652
DiseaseMarles Greenberg Persaud syndrome

FREM1 FREM2

1.56e-0521172C1855425
DiseaseDepressive disorder

RELN PDE4B HTR4 OAS2 ADCY8 ABCB1 BRCA1 IL1A

2.08e-052891178C0011581
DiseaseColorectal Carcinoma

ARFGEF1 LRRC4 ADCY8 HPS3 ABCB1 GHRHR TGM2 MLH3 SACS ACKR3 TLR4 EDRF1

2.35e-0570211712C0009402
DiseaseFraser syndrome (implicated_via_orthology)

FREM1 FREM2

9.30e-0541172DOID:0090001 (implicated_via_orthology)
DiseaseHereditary breast ovarian cancer syndrome

BRCA1 BRCA2

9.30e-0541172cv:C0677776
DiseaseBipolar Disorder

DOK5 RELN PDE4B HTR4 ADCY8 TGM2 BRCA2 TLR4 GNAL

1.24e-044771179C0005586
Diseasehereditary breast ovarian cancer syndrome (is_implicated_in)

BRCA1 BRCA2

1.55e-0451172DOID:5683 (is_implicated_in)
DiseaseAdult only

BRCA1 BRCA2

2.31e-0461172C3842001
Diseasedrug use measurement, quality of life during menstruation measurement

IL1A SDK1

3.23e-0471172EFO_0007010, EFO_0009366
Diseaselifestyle measurement

DOCK3 PDE4B HTR4 AFF3 FREM1 TLR4

3.59e-042351176EFO_0010724
DiseaseUnilateral agenesis of kidney

FREM1 FREM2

4.30e-0481172C0266294
Diseaseallergic rhinitis (is_implicated_in)

ABCB1 TLR4

4.30e-0481172DOID:4481 (is_implicated_in)
Diseasefamilial Mediterranean fever (is_implicated_in)

ABCB1 TLR4

5.51e-0491172DOID:2987 (is_implicated_in)
DiseasePancreatic carcinoma, familial

BRCA1 BRCA2

5.51e-0491172C2931038
Diseasecholesteatoma (is_marker_for)

TLR4 IL1A

6.87e-04101172DOID:869 (is_marker_for)
DiseaseFanconi anemia (is_implicated_in)

BRCA1 BRCA2

6.87e-04101172DOID:13636 (is_implicated_in)
Diseaselevel of Sphingomyelin (d34:0) in blood serum

PELP1 SYNE2

8.38e-04111172OBA_2045176
Diseaseanxiety disorder, stress-related disorder

PDE4B SDK1

1.00e-03121172EFO_0006788, EFO_0010098
Diseasealcohol and nicotine codependence

RGPD2 RGPD1

1.18e-03131172EFO_0004776
DiseaseBenign tumor of pancreas

BRCA1 BRCA2

1.18e-03131172C0347284
Diseaseage at first birth measurement

DOCK3 PDE4B FREM1 SDK1

1.35e-031201174EFO_0009101
Diseasenephroblastoma (is_implicated_in)

DIS3L2 BRCA2

1.38e-03141172DOID:2154 (is_implicated_in)
DiseaseHereditary Breast and Ovarian Cancer Syndrome

BRCA1 BRCA2

1.38e-03141172C0677776
Diseaseacute graft vs. host disease, donor genotype effect measurement

EYS SDK1

1.58e-03151172EFO_0004599, EFO_0007892
DiseaseDisorder of eye

GPR143 FREM1 FREM2 EYS CLN3

1.60e-032121175C0015397
Diseasecholesteatoma of middle ear (is_marker_for)

TLR4 IL1A

1.80e-03161172DOID:10964 (is_marker_for)
Diseaseovarian neoplasm

PRC1 BRCA1 BRCA2 TLR4

2.03e-031341174C0919267
DiseaseAlzheimer disease, brain volume measurement

PDS5B ADCY8

2.04e-03171172EFO_0006930, MONDO_0004975
DiseaseMalignant neoplasm of ovary

PRC1 BRCA1 BRCA2 TLR4

2.20e-031371174C1140680
Diseaseeosinophil percentage of granulocytes

DOCK3 HTR4 FARP2 PRKDC APBB1IP

2.45e-032341175EFO_0007996
Diseaseceramide measurement

SLCO5A1 EYS SYNE2 TMEM268 SDK1

2.50e-032351175EFO_0010222
DiseasePancreatic carcinoma

BRCA1 BRCA2

2.55e-03191172C0235974
Diseasecerebral microbleeds

ABCB1 OSBPL5

2.55e-03191172EFO_0010059
DiseaseSchizophrenia

RELN PDE4B RAPGEF6 HTR4 SBNO2 ABCB1 TGM2 BRCA1 TLR4 GNAL

2.74e-0388311710C0036341
Diseasebasophil count, eosinophil count

DOCK3 HTR4 FARP2 PRKDC APBB1IP

2.78e-032411175EFO_0004842, EFO_0005090
DiseaseAdenocarcinoma of prostate

BRCA1 BRCA2

2.83e-03201172C0007112
Diseaseamyloid-beta measurement

DOK5 AFF3 KCNV1 ACKR3 PRKDC SDK1

2.97e-033551176EFO_0005194
DiseaseBREAST CANCER

BRCA1 BRCA2

3.12e-03211172114480
DiseaseEsophageal Neoplasms

ABCB1 TGM2 MLH3

3.72e-03781173C0014859
DiseaseMalignant neoplasm of esophagus

ABCB1 TGM2 MLH3

3.72e-03781173C0546837
DiseaseAutistic Disorder

RELN PDE4B CUL7 FARP2 UBE2H

3.91e-032611175C0004352

Protein segments in the cluster

PeptideGeneStartEntry
LALLQEWDLESLCVY

AFF3

6

P51826
CWINETYLARNVIIF

ADCY8

776

P40145
QLLLQSYFQAWCEVV

C1orf167

1021

Q5SNV9
EWGQIFILDCLSNYN

AP2B1

216

P63010
LYTLFICITQDGWVD

CATSPER4

251

Q7RTX7
VDLIDLDLCNSTQWY

ACR

201

P10323
VLACLDTTQELWIYQ

ACTR8

591

Q9H981
VLLDDIFAQLYWCVQ

ARFGEF1

1476

Q9Y6D6
NVDWCLYEIYPELQI

APBB1IP

216

Q7Z5R6
AYSWDFLVQCIERLL

CCNJ

221

Q5T5M9
NVCLAWNYRDALAVI

ADPRM

251

Q3LIE5
YANTLFICRIVDWKE

DIS3L2

296

Q8IYB7
FVKLDNWLNELETYC

RAB18

96

Q9NP72
LLENIAWVKSYNICF

PDS5B

131

Q9NTI5
LLENLAWVKSYNICF

PDS5A

141

Q29RF7
YSEENLLFWLACEDL

RGS17

106

Q9UGC6
ILIQSLDWETFEQYC

INTS3

796

Q68E01
EEAALYIQSFWRACV

IQCK

216

Q8N0W5
IIAELLYSLQWCEEL

LTN1

1026

O94822
LVAAYIQVSFWCLAA

ABCB1

126

P08183
TVDNYAVLQLDIVWC

NUB1

276

Q9Y5A7
AVLQLDIVWCYFRLE

NUB1

281

Q9Y5A7
LYVTDLATQNWCELQ

EXO5

81

Q9H790
NLFIATKQDYWVCLA

IL1A

241

P01583
ALKLLQYCLADAWVA

SLC46A1

321

Q96NT5
VNWTLTENICLDFYR

EYS

41

Q5T1H1
KYVVCVLFVFWNLLD

HACD4

111

Q5VWC8
NVLTGIDYWLDNLIC

EDRF1

346

Q3B7T1
IDYWLDNLICNVPEL

EDRF1

351

Q3B7T1
VCQEAVWEAYRIFLD

IMPG1

101

Q17R60
RLLQATEYWACLQVA

LRRN2

586

O75325
NLDFTEICVNTILYW

ASB17

86

Q8WXJ9
FYRNLNLEACLWEFV

FREM2

2626

Q5SZK8
SLLCQLWGLYESIQD

FAM89B

106

Q8N5H3
AIYCLTQNEWRLDEA

DCUN1D2

26

Q6PH85
ELSQLQELLCNGYWA

HMGXB3

856

Q12766
EQLCALSFLQEIQYW

KCNV1

126

Q6PIU1
ITRASFCNVYLEWIQ

PCNX2

1591

A6NKB5
TLIEFQNWDTLLFCI

MLH3

326

Q9UHC1
LDWCLDQLETIQTYR

PDE4B

226

Q07343
GISLEDWLCAQYLAF

PEAK1

1716

Q9H792
WRSYLENLENLFQCL

PCED1B

136

Q96HM7
GWLLDQYLECQEAVF

CUL7

1066

Q14999
FILWVYLLEPDCNII

FREM1

121

Q5H8C1
QLCFSWLQYEIAKVI

NRDE2

731

Q9H7Z3
SDVLLYQVNCNAWLL

MEGF8

1811

Q7Z7M0
WLQALLKIYDCLQEF

MPP4

61

Q96JB8
FVYLTAQVWILCAAI

LRRC4

21

Q9HBW1
ALQITYEYICLWDVQ

DOK5

156

Q9P104
WEYIIGFCDQINKEL

GGA3

26

Q9NZ52
LDLAQLFIWVLREYN

GFUS

221

Q13630
QWCLYELDKEEFQTF

NLRP5

66

P59047
SLVQENLYFQRCLDW

PADI2

536

Q9Y2J8
EFGLVWHEIVNYICQ

P2RY12

181

Q9H244
NYICQVIFWINFLIV

P2RY12

191

Q9H244
LELVTQYQQLCIFWK

OAS2

596

P29728
VYAILELWVQVCGAS

PELP1

431

Q8IZL8
AQVACDVLQLLVSYW

RALGAPA2

1201

Q2PPJ7
GEVYEACWALDNILI

RELN

336

P78509
FLNDWNSIARLYECV

MED14

766

O60244
WIQCFNDVTAIIYVA

GNAL

221

P38405
VTCVEYAISWLQDLI

PARP14

1436

Q460N5
EWVLDSVALYQCQEL

BRCA1

1836

P38398
EPQDIYWLAQCLYLT

CDC16

36

Q13042
FLPVEDLYWNLSLVC

FBH1

226

Q8NFZ0
ALFFVLCWIQDEIVL

C2orf92

6

A0A1B0GVN3
EAAFTLLLYCELLQW

DOCK3

1256

Q8IZD9
ECYNLLAIKFWIDLN

BRCA2

3096

P51587
TANYLVIWCIDLEVE

CDC37

186

Q16543
LWNFLLLCTVIYFHQ

FITM1

231

A5D6W6
LVFGLVVTYDWDCQL

FCGBP

581

Q9Y6R7
NAEVWAYLALVCLKV

CFAP70

1066

Q5T0N1
CWLSNIINESLLFYL

GPR143

256

P51810
IFSWACVNYELDNKI

GUCY2F

146

P51841
CYILNLAIADLWVVL

ACKR3

81

P25106
LVQDIWIYGEVFCLV

HTR4

81

Q13639
NFSWLLAEAVYLNCL

GHRHR

216

Q02643
LVACIIVLGFNYWIA

GOLM1

21

Q8NBJ4
QLFWDIYVDCVLSRN

FAM237A

96

A0A1B0GTK4
TQVWKRLNLVECDYF

FARP2

71

O94887
WAEYILFAALLLVVC

SLC15A1

646

P46059
EVNYCLVTDLIIWTQ

SDK1

826

Q7Z5N4
LLQNAVIYSISCDWV

SACS

556

Q9NZJ4
WQALSELAALCYVIA

RGPD1

301

P0DJD0
WENTLENCYQSILEL

NOSTRIN

201

Q8IVI9
WFLLCVFLACQLFIN

OSBPL5

861

Q9H0X9
ENIFYLFWVLEQLLQ

MEI4

311

A8MW99
LSFEYLIQLCQSKEW

SZT2

951

Q5T011
CQFVCIAQQDYWRIL

RAPGEF6

366

Q8TEU7
LQKVLACWATYVENL

SYNE2

581

Q8WXH0
QLLVDFWEAQLVACL

HPS3

776

Q969F9
NVQWQALSELAALCY

RGPD2

306

P0DJD1
AIRVELVQYWDQCFY

PRC1

296

O43663
ILACLFVELFQSWQI

RHBDF1

726

Q96CC6
FILYELDSPLCWNEV

SLC46A3

281

Q7Z3Q1
WVYVALFICAQILIG

SLCO5A1

261

Q9H2Y9
CATVIIFWVAYRNED

SPPL2C

331

Q8IUH8
CVYNRAALLWAEALN

SBNO2

501

Q9Y2G9
VRIWDYTQDACINIL

WDR17

591

Q8IZU2
LQCLNLVFLLADVWF

CLN3

351

Q13286
YLRECAKANDWLQFI

SPG11

1361

Q96JI7
ILLFNAWCPADAVYL

TGM2

136

P21980
LWFVYFDLENCVQFL

TMEM268

196

Q5VZI3
QQVQVDCHFLQLYLW

VPS51

726

Q9UID3
FNELQYWVATELCLC

RAPGEF3

711

O95398
PILYVIQNEVDAFWC

TBC1D17

426

Q9HA65
LEEWSLLNEAQRCLY

ZNF586

26

Q9NXT0
WTCLQLDLQDVLLVY

WDR90

141

Q96KV7
VCLDVINQTWTALYD

UBE2H

86

P62256
TYNQQLWLTCVVELD

TMEM181

206

Q9P2C4
AWVLQDALGIAFCLY

SPPL2B

321

Q8TCT7
LDGSAYLECLQNLIW

SUSD4

216

Q5VX71
TVVSQVLCFLAIEWY

TRPV2

481

Q9Y5S1
DCLWILAAVAVYFAD

XKR4

111

Q5GH76
NNWTYTCIDLLDLVR

PKHD1L1

786

Q86WI1
WNYGQFEDKIIDICL

TGM5

181

O43548
WLDLLLAALECYNTF

PRKDC

1256

P78527
QEEWNLLSEAQRCLY

ZNF587B

26

E7ETH6
NVVRYCLEALQDWFD

UBR3

601

Q6ZT12
QEEWSLLSEVQRCLY

ZNF418

16

Q8TF45
IEYSAVFWERCNELQ

SMARCA5

881

O60264
FIQSRWCIFEYEIAQ

TLR4

741

O00206
VALLYLEQEDAFWCL

TBC1D2B

761

Q9UPU7
LRLYLADSWNQCDLV

TRPM4

856

Q8TD43
CVSQYANWLVVLLLV

TRPM4

1011

Q8TD43
VDLWDIACQIFVAIL

MYO7B

1661

Q6PIF6